{"id":403657,"date":"2025-08-28T00:00:00","date_gmt":"2025-08-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0048-2025-biopharma-myasthenia-gravis-current-treatment-treatment-algorithms-claims-data-analysis-myasthenia\/"},"modified":"2026-03-31T10:25:13","modified_gmt":"2026-03-31T10:25:13","slug":"algocg0048-2025-biopharma-myasthenia-gravis-current-treatment-treatment-algorithms-claims-data-analysis-myasthenia","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0048-2025-biopharma-myasthenia-gravis-current-treatment-treatment-algorithms-claims-data-analysis-myasthenia\/","title":{"rendered":"Myasthenia Gravis &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Myasthenia Gravis (US)"},"content":{"rendered":"<p>Myasthenia gravis (<abbr title=\"myasthenia gravis\">MG<\/abbr>) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. <abbr title=\"myasthenia gravis\">MG<\/abbr> is characterized by muscle weakness and fatigue. Acetylcholinesterase inhibitors (e.g., pyridostigmine), corticosteroids (e.g., prednisone), and short- and long-term immunosuppressants (e.g., mycophenolate mofetil, azathioprine) are the most prescribed agents to manage <abbr title=\"myasthenia gravis\">MG<\/abbr> symptoms. Since the launch of eculizumab (Alexion \/ AstraZeneca\u2019s Soliris) in 2017, a new wave of <abbr title=\"myasthenia gravis\">MG<\/abbr> therapies with unique mechanisms of action are starting to affect the treatment landscape. The <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approved efgartigimod (Argenx\u2019s Vyvgart) in 2021 and its subcutaneous version in 2023, ravulizumab (Alexion \/ AstraZeneca\u2019s Ultomiris) in 2022, and rozanolixizumab (UCB\u2019s Rystiggo) and zilucoplan (UCB\u2019s Zilbrysq) in 2023. As <abbr data-abbreviation-entity=\"10277\" title=\"myasthenia gravis\">MG<\/abbr> treatment continues to evolve, this report analyzes real-world claims data to uncover prescribing trends.<\/p>\n<p><strong>Questions answered <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"myasthenia gravis\">MG<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"myasthenia gravis\">MG<\/abbr> patients?<\/li>\n<li>How have the new <abbr title=\"myasthenia gravis\">MG<\/abbr> therapies been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of <abbr title=\"myasthenia gravis\">MG<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"myasthenia gravis\">MG<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Markets covered: <\/strong>United States<\/p>\n<p><strong>Key drugs: <\/strong>Soliris, Vyvgart, Ultomiris, Rystiggo, Zilbrysq, pyridostigmine<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><b>Product <\/b><b>enhancement<\/b><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-403657","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neurology","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/403657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/403657\/revisions"}],"predecessor-version":[{"id":522890,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/403657\/revisions\/522890"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=403657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}